Marina Nunez

Summary

Affiliation: Wake Forest University School of Medicine
Country: USA

Publications

  1. ncbi request reprint Coinfection with hepatitis C virus increases lymphocyte apoptosis in HIV-infected patients
    Marina Nunez
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 43:1209-12. 2006
  2. doi request reprint Clinical syndromes and consequences of antiretroviral-related hepatotoxicity
    Marina Nunez
    Department of Internal Medicine, Wake Forest University Health Sciences, Winston Salem, NC 27157, USA
    Hepatology 52:1143-55. 2010
  3. ncbi request reprint Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial
    Marina Nunez
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain
    AIDS Res Hum Retroviruses 23:972-82. 2007
  4. ncbi request reprint Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C
    Marina Nunez
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 10:657-62. 2005
  5. ncbi request reprint Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families
    Carmen de Mendoza
    Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain
    HIV Clin Trials 3:304-9. 2002
  6. ncbi request reprint Evolution of T-cell responses to hepatitis C virus (HCV) during pegylated interferon plus ribavirin treatment in HCV-monoinfected and in HCV/HIV-coinfected patients
    Laura Capa
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 12:459-68. 2007
  7. ncbi request reprint Characteristics and prospects for hepatitis C therapy of an HIV-HCV coinfected population followed at a reference HIV center
    Ivana Maida
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 6:329-36. 2005
  8. ncbi request reprint Severe liver disease associated with prolonged exposure to antiretroviral drugs
    Ivana Maida
    Department of Infectious Diseases, Hospital Carlos III, Madrid Spain
    J Acquir Immune Defic Syndr 42:177-82. 2006
  9. ncbi request reprint Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C
    Luz Martin-Carbonero
    Hospital Carlos III, CIBERehd, Madrid, Spain
    AIDS 22:15-21. 2008
  10. ncbi request reprint Chronic hepatitis C in HIV-infected patients: those who more need therapy are those who respond less
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Infect Disord Drug Targets 6:57-88. 2006

Collaborators

Detail Information

Publications70

  1. ncbi request reprint Coinfection with hepatitis C virus increases lymphocyte apoptosis in HIV-infected patients
    Marina Nunez
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 43:1209-12. 2006
    ..Apoptosis in naive CD4(+) T cells and in naive and memory CD8(+) T cells was significantly higher in HIV-HCV-coinfected than in monoinfected patients...
  2. doi request reprint Clinical syndromes and consequences of antiretroviral-related hepatotoxicity
    Marina Nunez
    Department of Internal Medicine, Wake Forest University Health Sciences, Winston Salem, NC 27157, USA
    Hepatology 52:1143-55. 2010
    ..Updated information on liver toxicity of current antiretroviral drugs, including the most recently licensed, is provided. Management and prevention of liver toxicity among HIV-infected patients treated with HAART are reviewed as well...
  3. ncbi request reprint Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial
    Marina Nunez
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain
    AIDS Res Hum Retroviruses 23:972-82. 2007
    ..The use of RBV 1000-1200 mg/day plus pegIFN is relatively safe and provides SVR in nearly half of coinfected patients, twice as high in HCV-2/3 than HCV-1/4...
  4. ncbi request reprint Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C
    Marina Nunez
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 10:657-62. 2005
    ..The use of pegylated interferon (PEG-IFN) plus ribavirin (RBV) is currently the recommended treatment for chronic hepatitis C virus (HCV) infection. Coinfection with HIV is a negative predictor of response, for reasons not well understood...
  5. ncbi request reprint Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families
    Carmen de Mendoza
    Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain
    HIV Clin Trials 3:304-9. 2002
    ..It has shown greater potency than the former PIs in phase II/III trials, either in naive or in PI-experienced patients being naive for nonnucleoside reverse transcriptase inhibitors (NNRTIs)...
  6. ncbi request reprint Evolution of T-cell responses to hepatitis C virus (HCV) during pegylated interferon plus ribavirin treatment in HCV-monoinfected and in HCV/HIV-coinfected patients
    Laura Capa
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 12:459-68. 2007
    ..As in HIV infection, virus replication could drive or be contained by T-cell immunity. We have examined the effect of HIV coinfection and of suppression of HCV replication with therapy on HCV-specific T-cell responses...
  7. ncbi request reprint Characteristics and prospects for hepatitis C therapy of an HIV-HCV coinfected population followed at a reference HIV center
    Ivana Maida
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 6:329-36. 2005
    ..A cross-sectional study was performed during 2004 at a large HIV clinic in Spain to identify HIV-HCV coinfected individuals who might be candidates for HCV therapy...
  8. ncbi request reprint Severe liver disease associated with prolonged exposure to antiretroviral drugs
    Ivana Maida
    Department of Infectious Diseases, Hospital Carlos III, Madrid Spain
    J Acquir Immune Defic Syndr 42:177-82. 2006
    ..However, the etiology of liver disease still remains unknown for a small subset of individuals...
  9. ncbi request reprint Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C
    Luz Martin-Carbonero
    Hospital Carlos III, CIBERehd, Madrid, Spain
    AIDS 22:15-21. 2008
    ..It is unclear whether this applies to HIV/HCV-co-infected patients...
  10. ncbi request reprint Chronic hepatitis C in HIV-infected patients: those who more need therapy are those who respond less
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Infect Disord Drug Targets 6:57-88. 2006
    ..The relatively low efficacy of current anti-HCV medications and their low tolerability clearly indicated the need for new drugs with more potent and direct antiviral activity against HCV...
  11. ncbi request reprint Liver fibrosis in HIV-infected patients with chronic hepatitis B extensively exposed to antiretroviral therapy with anti-HBV activity
    Ivana Maida
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 7:246-50. 2006
    ..The extent and predictors of liver fibrosis were examined in a HIV/HBVcoinfected cohort with extensive exposure to anti-HBV active HAART...
  12. ncbi request reprint Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy
    Pablo Barreiro
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 4:361-71. 2003
    ....
  13. ncbi request reprint Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients
    Belen Ramos
    Service of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    J Acquir Immune Defic Syndr 44:557-61. 2007
    ..Information available on the prevalence and distribution of distinct HBV variants in HIV-positive patients is scarce...
  14. ncbi request reprint Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies
    Vincent Soriano
    Service of Infectious Diseases, Hospital Carlos II, Madrid, Spain
    Antivir Ther 9:987-92. 2004
    ..However, the occurrence of liver complications (including hepatocellular carcinoma) and/or HCV relapses in coinfected patients when followed for long periods of time after HCV therapy is not well known...
  15. ncbi request reprint Virological characteristics of hepatitis C virus infection in HIV-infected individuals with chronic hepatitis C: implications for treatment
    Mayte Pérez-Olmeda
    Infectious Disease Service, Hepatology Unit, Institute de Salud Carlos III, Madrid, Spain
    AIDS 16:493-5. 2002
  16. ncbi request reprint Failure of hepatitis C therapy in HIV-coinfected drug users is not due to a shift in hepatitis C virus genotype
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Infect Dis 192:1245-8. 2005
    ..Coinfection with distinct HCV genotypes is unlikely in former IDUs coinfected with HIV and does not explain the lower efficacy of HCV therapy in this population...
  17. ncbi request reprint Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy
    Marina Nunez
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 22:842-8. 2006
    ..Thus, HBV/HIV-coinfected patients might benefit from an earlier introduction of HAART...
  18. ncbi request reprint Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3
    Pablo Barreiro
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 42:1032-9. 2006
    ..The reasons for this faster liver disease progression are unclear, although higher plasma HCV RNA levels and distinct HCV genotype distribution in this population, compared with in HCV-monoinfected subjects, could play a role...
  19. ncbi request reprint Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients
    Ana Lucía Rendon
    Pharmacy Service, Hospital Carlos III, Madrid, Spain
    J Acquir Immune Defic Syndr 39:401-5. 2005
    ..Therefore, early therapeutic drug monitoring might help to tailor RBV dosages, improving the efficacy and safety of anti-HCV treatment...
  20. ncbi request reprint Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine
    Marina Nunez
    Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
    AIDS 16:2352-4. 2002
    ..HBV-DNA levels dropped a median of 3.78 logs from baseline to 24 weeks. Tenofovir was very effective at reducing HBV-DNA levels in HIV/HBV-co-infected patients carrying either wild-type or lamivudine-resistant viruses...
  21. ncbi request reprint Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients
    Mayte Pérez-Olmeda
    Service of Infectious Diseases and bHepatology Unit, Instituto de Salud Carlos III, Madrid, Spain
    AIDS 17:1023-8. 2003
    ..Treatment of hepatitis C virus (HCV) has become a major challenge in HIV-infected individuals. No data exist on the efficacy and tolerability of pegylated IFN (peg-IFN) plus ribavirin in HIV-co-infected patients...
  22. ncbi request reprint New paradigms in the management of HIV and hepatitis C virus coinfection
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    Curr Opin Infect Dis 18:550-60. 2005
    ..The bidirectional interferences between hepatitis C virus and HIV have clinical consequences and complicate the management of coinfected individuals...
  23. ncbi request reprint Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future
    Marina Nunez
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 37:1678-85. 2003
    ..Preliminary results with some of them are quite promising and probably will widen the therapeutic armamentarium against hepatitis B in patients with HIV infection...
  24. ncbi request reprint SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals
    Marina Nunez
    Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain
    HIV Clin Trials 3:186-94. 2002
    ..A randomized, open-label, pilot study was undertaken to explore the antiviral activity and tolerability of two nonnucleoside reverse transcriptase inhibitors (NNRTIs), nevirapine (NVP) and efavirenz (EFV)...
  25. ncbi request reprint Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution
    Luz Martin-Carbonero
    Service of Infectious Diseases Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain
    AIDS 16:1423-5. 2002
    ..Underlying chronic hepatitis may thus increase the risk of liver toxicity by other mechanisms...
  26. ncbi request reprint Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy
    Marina Nunez
    Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain
    J Acquir Immune Defic Syndr 30:65-8. 2002
    ..To assess the role of different hepatitis C virus (HCV) genotypes in the development of transaminase elevation after treatment with highly active antiretroviral therapy (HAART)...
  27. ncbi request reprint Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine
    Ana Barrios
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS 19:569-75. 2005
    ..The popularity of this combination, however, has been questioned due to concerns about pharmacokinetic interactions and increased risk of pancreatitis and hyperglycemia. Less information is available about other possible side effects...
  28. ncbi request reprint Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4
    Vincent Soriano
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 10:167-70. 2005
    ..HCV genotype 4 is spreading among European intravenous drug users, who are frequently coinfected with HIV. Information about treatment response in this subset of patients is scarce and conflicting results have been reported...
  29. ncbi request reprint Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin
    Vincent Soriano
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 9:505-9. 2004
    ..Therefore, extending therapy (for 12 months in HCV genotypes 2/3 and perhaps for 18 months in HCV genotypes 1/4) might be warranted in HIV/HCV-coinfected patients showing EVR...
  30. doi request reprint Virological rather than host factors are associated with transaminase levels among HIV/HCV-coinfected patients
    Nathan J Shores
    Division on Gastroenterology, Department of Internal Medicine, Wake Forest University Health Sciences, Winston Salem, NC 27157, USA
    J Int Assoc Physicians AIDS Care (Chic) 9:15-9. 2010
    ..Hepatitis C viral factors rather than race were associated with ALT levels in this HIV/HCV-coinfected population. ALT were within normal limits in 18% of patients, who more often were male and had lower Hepatitis C viral load...
  31. doi request reprint Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy
    Kari Yacisin
    Wake Forest University Health Sciences, Winston Salem, North Carolina 27157, USA
    AIDS Res Hum Retroviruses 24:935-40. 2008
    ..Lower baseline CD4 counts are the strongest predictors of greater CD4 gains over a 3-year period, while a history of IVDU negatively affects CD4 restoration only early after the initiation of HAART...
  32. ncbi request reprint Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients
    Marina Nunez
    Department of Infectious Diseases, Instituto de Salud Carlos III, 28035 Madrid, Spain
    AIDS Res Hum Retroviruses 19:187-8. 2003
    ..8 [0.7-29] vs. 6.1 [0.9-9.6] microg/ml). Thus, HCV coinfection itself does not seem to influence significantly the pharmacokinetics of NVP in HIV-infected subjects...
  33. ncbi request reprint Influence of HCV genotype and co-infection with human immunodeficiency virus on CD4(+) and CD8(+) T-cell responses to hepatitis C virus
    Laura Capa
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Med Virol 79:503-10. 2007
    ..Both the prevalence and breadth of CD4(+) and CD8(+) responses were lower in co-infected patients, independently of the HCV genotype...
  34. pmc Different viral rebound following discontinuation of antiretroviral therapy in cases of infection with viruses carrying L74V or thymidine-associated mutations
    Carmen de Mendoza
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Clin Microbiol 42:862-6. 2004
    ..01) in 12 subjects harboring thymidine-associated mutations; these mutations persisted in all instances. Thus, selection of an L74V mutation during didanosine therapy may compromise HIV replication in vivo...
  35. ncbi request reprint Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: implications for HCV therapy in HCV/HIV-coinfected patients
    Belen Ramos
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    J Infect 54:173-9. 2007
    ..Changes in the prevalence of distinct hepatitis C virus (HCV) genotypes and subtypes over time have not been explored in detail...
  36. ncbi request reprint Does an increase in nevirapine plasma levels cause complete virologic suppression in patients experiencing early virologic failure?
    Daniel Gonzalez de Requena
    Service of Pharmacy, Instituto de Salud Carlos III, Madrid, Spain
    HIV Clin Trials 3:463-7. 2002
    ..Patients on two nucleoside analogs plus nevirapine (NVP) who show low-level plasma HIV RNA might have insufficient NVP plasma levels and therefore might benefit from an increase in NVP dosing...
  37. ncbi request reprint Liver toxicity caused by nevirapine
    Daniel Gonzalez de Requena
    Service of Pharmacy, Instituto de Salud Carlos III, Madrid, Spain
    AIDS 16:290-1. 2002
    ..Therefore, monitoring nevirapine levels, especially in individuals with chronic hepatitis C, may be warranted...
  38. ncbi request reprint Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir
    Julie Sheldon
    Hospital Carlos Ill, Madrid, Spain
    Antivir Ther 10:727-34. 2005
    ..The aim of this study was to analyse the HBV polymerase (pol) from HIV/HBV-coinfected patients with detectable serum levels of HBV DNA during treatment with TDF for longer than 6 months...
  39. doi request reprint First HAART in HIV-infected patients with high viral load: value of HIV RNA levels at 12 weeks to predict virologic outcome
    David Townsend
    Wake Forest University Health Sciences, Winston Salem, NC 27157, USA
    J Int Assoc Physicians AIDS Care (Chic) 8:314-7. 2009
    ..HIV RNA >500 copies/mL at week 12 of first HAART predicts incomplete virologic response in patients with high levels of replication at baseline. Most patients carried resistance mutations at the time of failure...
  40. ncbi request reprint Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors
    Pablo Barreiro
    Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
    Int J Antimicrob Agents 20:438-43. 2002
    ..The efficacy of rit-boosted PI combinations is greatly influenced by the extent of baseline PI resistance. Differences, not only in potency, but mainly in tolerance may favour the selection of one dual PI combination over others...
  41. ncbi request reprint Hepatitis C viremia in HIV/HCV-coinfected patients: lower levels in presence of chronic hepatitis B
    Marina Nunez
    Service of Infectious Diseases, Hospital Carlos III, C Sinesio Delgado 10, 28029 Madrid, Spain
    HIV Clin Trials 6:103-6. 2005
    ..We examined the influence of HBV on HCV RNA titers in 376 HCV/HIV-coinfected patients (30 were also HBsAg positive). Regression analyses identified negative HBsAg and male sex as factors associated with HCV RNA values >500,000 IU/mL...
  42. ncbi request reprint Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin
    Vincent Soriano
    Hospital Carlos III, Madrid, Spain
    Antivir Ther 12:469-76. 2007
    ..Chronic hepatitis C therapy in HIV patients is often penalized by more frequent premature treatment discontinuations. It is unclear what the relative contribution of more adverse events and/or early virological failures are...
  43. doi request reprint Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients
    Nathan J Shores
    Division of Gastroenterology, Department of Medicine, Wake Forest University Health System, Winston Salem, NC, USA
    J Hepatol 49:323-8. 2008
    ..The aim of this study was to determine the epidemiological factors that predict the resolution of acute HCV infection without therapy in patients with human immunodeficiency virus (HIV) infection...
  44. ncbi request reprint Longer duration of HBV-active antiretroviral therapy is linked to favorable virological outcome in HIV-HBV co-infected patients
    Tsan Lee
    Wake Forest University School of Medicine, Winston Salem, North Carolina, USA
    HIV Clin Trials 10:153-9. 2009
    ..HBV-HIV co-infection is associated with increased liver-related morbidity and mortality. Herein we analyzed HBV-related virologic and clinical outcomes in HBV-HIV patients in the HAART era...
  45. ncbi request reprint Liver fibrosis stage and HCV genotype distribution in HIV-HCV coinfected patients with persistently normal transaminases
    Ivana Maida
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 23:801-4. 2007
    ..9% show persistently normal ALT levels. Nearly 25% of HIV-HCV-coinfected patients with persistently normal ALT show advanced liver fibrosis. Therefore, HCV-HIV-coinfected patients with normal ALT levels should be closely monitored...
  46. ncbi request reprint Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations
    Marina Nunez
    Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
    Med Sci Monit 8:CR620-3. 2002
    ..The purpose of our study was to assess the presence of nelfinavir (NFV)-associated resistance mutations at the time of early virological failure in subjects receiving NFV as part of a first protease inhibitor (PI)-based triple regimen...
  47. ncbi request reprint Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study
    Luz Martin-Carbonero
    Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 38:128-33. 2004
    ..The rate of complications due to end-stage liver disease will inevitably increase in this population, for whom anti-HCV therapy should be considered a priority...
  48. ncbi request reprint Nelfinavir plasma concentrations in patients experiencing early failure with nelfinavir-containing triple combinations
    Daniel Gonzalez de Requena
    Pharmacology Unit, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain
    AIDS 17:442-4. 2003
  49. doi request reprint Outcome of HCV genotype 1 treatment in HIV-coinfected patients with chronic kidney disease
    Ana Paula Oppenheimer
    Department of Internal Medicine, Section on Infectious Diseases, Wake Forest Baptist Medical Center, Winston Salem, NC 27157, USA
    J Int Assoc Provid AIDS Care 12:55-7. 2013
    ..Of the 7 patients, 2 achieved sustained virological response. None of the responders had end-stage renal disease, suggesting that HCV treatment is most likely to be successful in earlier stages of renal disease...
  50. ncbi request reprint Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine
    Luz Martin-Carbonero
    Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain
    HIV Clin Trials 4:115-20. 2003
    ..To compare the incidence and define the risk factors associated with liver toxicity in patients beginning treatment with nevirapine (NVP) and efavirenz (EFZ)...
  51. ncbi request reprint Short communication: liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection
    Daniel González-Requena
    Service of Infectious Diseases and Pharmacy Unit, Hospital Carlos III, 28035 Madrid, Spain
    AIDS Res Hum Retroviruses 20:698-700. 2004
    ..The incidence of severe liver toxicity at 3 months was 1.7% and the cumulative incidence at 12 months was 4%. The development of severe liver toxicity was associated with HCV coinfection but not with LPV plasma levels...
  52. ncbi request reprint Complications in treating chronic hepatitis B in patients with HIV
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    Expert Opin Pharmacother 6:2831-42. 2005
    ..Although response to IFN-alpha is poorer in HBV/HIV-coinfected patients compared with HBV-monoinfected individuals, the more potent pegylated forms of IFN-alpha have brought new hopes...
  53. doi request reprint Viral hepatitis and HIV: update and management
    Marina Nunez
    Infectious Diseases, Wake Forest University Health Sciences, Winston Salem, NC, USA
    Antivir Ther 18:451-8. 2013
    ..HBV-active HAART improves the outcome of patients with HIV-HBV coinfection and tenofovir has become a key component of the treatment for these patients, although a number of clinical situations require a case-by-case approach. ..
  54. ncbi request reprint New hopes for HIV and HCV coinfection in 2004
    Marina Nunez
    Service of Infectious Diseases Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 5:232-51. 2004
    ..New anti-HCV drugs are urgently needed and new strategies with the currently available drugs need to be assessed to reduce the negative impact of hepatitis C in HIV-coinfected individuals...
  55. ncbi request reprint Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy
    Pablo Barreiro
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Acquir Immune Defic Syndr 43:324-6. 2006
    ..Serodiscordant couples attaining natural pregnancy are exposed to a negligible risk of sexual transmission of HIV when the infected partner presents with complete suppression of plasma viremia while receiving HAART...
  56. ncbi request reprint Management of patients co-infected with hepatitis B virus and HIV
    Marina Nunez
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Lancet Infect Dis 5:374-82. 2005
    ....
  57. ncbi request reprint Management of chronic hepatitis B and C in HIV-coinfected patients
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    J Antimicrob Chemother 57:815-8. 2006
    ..Several guidelines have recently been released in response to this demand. In this article, we discuss the most critical issues highlighted in these documents...
  58. pmc JC polyoma virus interacts with APOL1 in African Americans with nondiabetic nephropathy
    Jasmin Divers
    Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston Salem, North Carolina, USA
    Kidney Int 84:1207-13. 2013
    ....
  59. pmc Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease
    Barry I Freedman
    Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston Salem, North Carolina 27157 1053, USA
    Kidney Int 82:805-11. 2012
    ..After adjustment, two APOL1 risk variants weakly predict mild forms of kidney disease. Second hits appear necessary for the initiation of APOL1-associated nephropathy...
  60. ncbi request reprint Highlights from the 1st International Workshop on HIV and Hepatitis Co-infection
    Marina Nunez
    Service of Infectious Diseases, Hospital Carlos III, C Sinesio Delgado 10, 28029 Madrid, Spain
    HIV Clin Trials 6:118-25. 2005
  61. ncbi request reprint [Advances in the diagnosis and treatment of the infection by the hepatitis B virus]
    Marina Nunez
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Spain
    Enferm Infecc Microbiol Clin 22:539-49. 2004
    ..While the selection of lamivudine resistance mutations is frequent, adefovir has a high genetic barrier. HIV infection negatively impacts on HBV disease, requiring these coinfected patients strategies aimed to manage both viruses...
  62. ncbi request reprint Current concepts in the management and treatment of hepatitis C in HIV-infected patients
    Marina Nunez
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Ann Hepatol 4:151-60. 2005
    ..Finally, new anti-HCV drugs currently under development are eagerly awaited for the growing number of HCV/HIV-coinfected patients non-responders or relapsers to the current therapy...
  63. doi request reprint Liver toxicity of antiretroviral drugs
    Michelle Jones
    Section on Infectious Diseases, Department of Internal Medicine, Wake Forest University Health Sciences, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Semin Liver Dis 32:167-76. 2012
    ..Nevertheless, with an aging human immunodeficiency virus- (HIV-) infected population and increased survival, DILI will probably continue to represent a relevant entity in e HIV therapeutic management...
  64. doi request reprint HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management
    Michelle Jones
    Department of Internal Medicine, Section on Infectious Diseases, Wake Forest University Baptist Medical Center, Winston Salem, North Carolina 27157, USA
    Curr Opin HIV AIDS 6:546-52. 2011
    ..Antiretroviral therapy might have a positive effect on the liver of HIV/HCV co-infected patients, but data are conflicting...
  65. ncbi request reprint Hepatotoxicity of antiretrovirals: incidence, mechanisms and management
    Marina Nunez
    Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
    J Hepatol 44:S132-9. 2006
    ..The management of liver toxicity is based mainly on its clinical impact, severity and pathogenic mechanism...
  66. doi request reprint Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin
    L Martin-Carbonero
    Dept of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 47:410-7. 2008
    ..However, this tumor still represents the most common cancer in this population...
  67. ncbi request reprint Hepatotoxicity of antiretrovirals: incidence, mechanisms and management
    Marina Nunez
    Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
    Drug Saf 28:53-66. 2005
    ....
  68. doi request reprint Levels of serum markers of liver inflammation and fibrosis in patients with chronic hepatitis C virus infection according to HIV status and antiretroviral use
    Abbie Connoy
    Department of Internal Medicine, Section on Infectious Diseases, Wake Forest University Health Sciences, Winston Salem, North Carolina, USA
    AIDS Res Hum Retroviruses 27:719-25. 2011
    ..In conclusion, serum markers of hepatic inflammation and fibrosis are overexpressed in HIV-HCV-coinfected patients with advanced immunosuppression, while HAART has a "protective" effect...
  69. ncbi request reprint Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients
    Vincent Soriano
    Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 20:351-3. 2004
    ..8% for HCV genotypes 1-4) and/or the use of either standard or pegylated IFN (37% versus 29%, respectively). Thus, extended periods of anti-HCV therapy might reduce HCV relapses in HIV-coinfected patients initially responding to therapy...
  70. pmc Gene-gene and gene-environment interactions in HIV-associated nephropathy: A focus on the MYH9 nephropathy susceptibility gene
    Marina Nunez
    Department of Internal Medicine, Wake Forest University School of Medicine, Winston Salem, NC 27157 1053, USA
    Adv Chronic Kidney Dis 17:44-51. 2010
    ..It is important that these novel risk factors be identified because prevention of environmental exposures and targeting of additional gene products may reduce the risk for HIVAN, even among those harboring 2 risk alleles in MYH9...